Medicilon and Hailu Biotech of Yangtze River Pharmaceutical Group Forge Strategic Cooperation to Accelerate New Drug R&D and Global Outreach

Medicilion Congratulates MediLink Therapeutics on Licensing B7H3 ADC to Roche

On March 30, Medicilon held a strategic cooperation signing ceremony with Suzhou Hailu Biotech, a wholly-owned subsidiary of Yangtze River Pharmaceutical Group. The collaboration will focus on deepening synergy in preclinical new drug R&D, project introduction, and global market expansion, with the goal of jointly building an efficient, open, and international R&D ecosystem spanning from source […]

Search Medicilon

Preclinical CRO

Medicilon Webinar | IND-enabling Toxicity Studies, CTD Documentation and Translational Cardiac Risk Assessment

Preclinical CRO

Medicilon Stands Out at ASMS 2026: Only CRO Selected for Bioanalysis Zone’s ‘Pick of the Posters’

Preclinical CRO

Medicilon Congratulates Livzon Pharmaceutical on the Approval of LiYouBao® — China’s Only Export-Qualified r-FSH Injection Meeting Global International Standards

Contact Medicilon

Name(Required)
Address(Required)